ClinicalTrials.gg
CompletedNCT03083665Updated Oct 14, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

A Phase 3 interventional study of Placebo and Brivaracetam in Partial Seizures With or Without Secondary Generalization and Epilepsy, sponsored by UCB Biopharma SRL. Completed at 94 sites in 7 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
449
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
6th of 34
449 · median 94
Started
2017
with 2 others
Phase 3
21 of 34
1 open now
Registered
22nd of 34
by date
Lead sponsor
7 of 34
UCB Biopharma SRL

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 6th largest by enrollment, is one of 3 that started in 2017, is one of 21 in phase 3, and was the 22nd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in subjects >= 16 years to 80 years of age.

03

Conditions studied

  • Partial Seizures With or Without Secondary Generalization
  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Partial seizures with or without secondary generalization
  • Brivaracetam
  • Briviact
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects (male or female) from 16 to 80 years of age at Visit 1, both inclusive
  • Female subjects with are eligible if they use a medically accepted method
  • Subjects having at least 8 partial seizures (according to the 1981 ILAE classification) during the 8-Week Baseline Period with at least 2 partial seizures during each 4-week interval of the Baseline Period
  • Subjects having at least 2 partial seizures whether or not secondary generalization per month during the 3 months preceding Visit 1
  • Subjects uncontrolled while treated by 1 or 2 permitted concomitant antiepileptic drug [AED](s). Vagal Nerve Stimulation (VNS) is allowed and will be counted as a concomitant AED

Exclusion criteria

Exclusion Criteria:

  • Subject has history or presence of status epilepticus during the year preceding Visit 1 or during Baseline
  • Subject is currently treated with levetiracetam
  • Subject has taken levetiracetam within 90 days prior to Visit 1
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
449 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    * 12 weeks Treatment Period: Subjects will receive Placebo * 4 weeks Down-Titration Period: Subjects will receive Placebo

    Drug: Placebo

  • Experimental
    BRV 50 mg/day

    12 weeks Treatment Period: Subjects will receive BRV 50 mg/day \- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 50 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day \- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 25 mg/day for 1 week followed by Placebo for 3 weeks, followed by a Study Drug-Free Period

    Drug: Placebo · Drug: Brivaracetam

  • Experimental
    BRV 200 mg/day

    12 weeks Treatment Period: Subjects will receive BRV 200 mg/day \- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 150 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day \- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 150 mg/day for 1 week followed by BRV 100 mg/day for 1 week, followed by BRV 50 mg/day for 1 week, followed by BRV 25 mg/day for 1 week followed by a Study Drug-Free Period

    Drug: Placebo · Drug: Brivaracetam

Interventions

  • DrugPlacebo

    * Pharmaceutical form: Film-coated tablets * Route of administration: Oral use

  • * Pharmaceutical form: Film-coated tablets * Concentration: 25 mg tablets and 50 mg tablets * Route of administration: Oral use

    Also known as: Briviact

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Treatment-Emergent AEs were defined as AEs which had onset on or after the first dose of IMP. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.

    Time frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)

  2. Percentage of Participants With Treatment-Emergent AEs (TEAEs) Leading to Study Withdrawal

    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Treatment-Emergent AEs were defined as AEs which had onset on or after the first dose of IMP. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.

    Time frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)

  3. Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)

    Serious Adverse event (SAE) was defined as any events which: • results in death, • is life-threatening threatening (note that this did not include a reaction that might have caused death had it occurred in a more severe form.), •results in significant or persistent disability/incapacity, • results in a congenital anomaly/birth defect (including that occurring in a fetus), • results in Important medical event that, based upon appropriate medical judgment, may jeopardize the participant and might require medical or surgical intervention to prevent 1 of the other outcomes listed here, and • results in initial inpatient hospitalization or prolongation of hospitalization. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.

    Time frame: From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)

  4. Partial Seizure Frequency Per 28 Days During the 12-week Treatment Period

    According to International League Against Epilepsy (ILAE) classification (1981), seizures were classified as type IA (IA1, IA2, IA3, and IA4), IB, IC, II (IIA, IIB, IIC, IID, IIE, and IIF) or III. 28 day adjusted seizure frequency for partial seizures (seizure types IA+IB+IC) was calculated for treatment period by dividing the number of partial seizures by the number of days for which the DRC was completed for treatment period and multiplying the resulting value by 28.

    Time frame: From Baseline to 12-week Treatment Period

Secondary outcomes

  1. 50% Responder Rate Based on Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period

    Responders were those participants with at least 50% reduction from Baseline to the 12-week Treatment Period in partial seizure frequency per 28 days. 50% Responder rate was calculated for treatment period by dividing the number of 50% responders by the number of participants in the analysis set and multiplying the resulting value by 100.

    Time frame: From Baseline to 12-week Treatment Period

  2. Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period

    Percent change from Baseline to the Treatment Period in partial seizure frequency was calculated by subtracting 28-day adjusted Treatment Period partial seizure frequency from 28-day adjusted Baseline Period partial seizure frequency, and multiplying the resulting quantity by 100 and dividing by the Baseline Period 28-day adjusted partial seizure frequency. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline to the Treatment Period.

    Time frame: From Baseline to 12-week Treatment Period

  3. Percentage of Participants With Categorized Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period

    The percentage of participants within each of the following categories of percent change in partial seizure frequency from Baseline to the Treatment Period were summarized for each treatment group: 100%, 75% to less than 100%, 50% to less than 75%, 25% to less than 50%, -25% to less than 25%, and less than -25%. Percent change from Baseline to the Treatment Period in partial seizure frequency was calculated by subtracting 28-day adjusted Treatment Period partial seizure frequency from 28-day adjusted Baseline Period partial seizure frequency and multiplying the resulting quantity by 100 and dividing by the Baseline Period 28-day adjusted partial seizure frequency.

    Time frame: From Baseline to 12-week Treatment Period

  4. All Seizure Frequency (Partial, Generalized, and Unclassified Epileptic Seizures) Per 28 Days During the 12-week Treatment Period

    There were three types of epileptic seizures: Partial epileptic seizures (Type I), Generalized epileptic seizures (Type II) and unclassified epileptic seizures (Type III). 28 day adjusted seizure frequency for all seizure types was calculated for treatment period by dividing the number of targeted seizures by the number of days for which the DRC was completed for treatment period and multiplying the resulting value by 28.

    Time frame: During the 12-week Treatment Period

  5. Percentage of Participants Who Are Seizure Free (Partial, All Epileptic Seizures) During the 12-week Treatment Period

    Participants were defined as seizure free, if they did not have missing diary days and no reported seizures during the Treatment Period.

    Time frame: During the 12-week Treatment Period

  6. Time to 1st Partial Seizure During the 12-week Treatment Period

    The evaluation of time to 1st partial seizure was based on the relative day of occurrence of the 1st partial seizure during the Treatment Period.

    Time frame: During the 12-week Treatment Period

  7. Time to 5th Partial Seizure During the 12-week Treatment Period

    The evaluation of time to 5th partial seizure was based on the relative day of occurrence of the 5th partial seizure during the Treatment Period.

    Time frame: During the 12-week Treatment Period

  8. Time to 10th Partial Seizure During the 12-week Treatment Period

    The evaluation of time to 10th partial seizure was based on the relative day of occurrence of the 10th partial seizure during the Treatment Period.

    Time frame: During the 12-week Treatment Period

  9. Brivaracetam Plasma Concentration

    Blood samples were collected at indicated time points for the 50mg/day and 200mg/day groups to determine the brivaracetam plasma concentration. Participants of arm 'BRV 200 mg/day' received BRV 200 mg/day until Week 12 only and 150 mg/day during the Transition Period at Week 14. Therefore, the data is reported according to the dosage information at specified time point. As per planned analysis, one blood sample was collected for BRV plasma levels during each dosing interval between 0 to 4 hours, 4 to 8 hours, and 8 to 12 hours postdose.

    Time frame: Plasma samples were collected at >0-4hours, >4-8hours, >8hours in weeks 2, 4, 8, 12, and 14

07

Results

Posted Nov 9, 2023

Participant flow

The study started to enroll participants in August 2017 and concluded in June 2022.

Double-Blind Period
Participant flow — Double-Blind Period
MilestonePlaceboBRV 50 mg/DayBRV 200 mg/DayPlacebo to OLTP BRVBRV 50 mg/Day to OLTP BRVBRV 200 mg/Day to OLTP BRV
Started149152148000
Started treatment period (12 weeks)149152148000
Started down-titration period (4 weeks)797000
Started study drug-free period (2 weeks)797000
Started transition period (2 weeks)133139137000
Completed138147140000
Not completed1158000
Withdrew: Adverse event545000
Withdrew: Lack of efficacy001000
Withdrew: Protocol violation101000
Withdrew: Lost to follow-up101000
Withdrew: Withdrawal by subject300000
Withdrew: Consent withdrawn by subject due to concern on ae100000
Withdrew: Subjects were able to never take a study drug010000
Open-Label Temporary Period (OLTP)
Participant flow — Open-Label Temporary Period (OLTP)
MilestonePlaceboBRV 50 mg/DayBRV 200 mg/DayPlacebo to OLTP BRVBRV 50 mg/Day to OLTP BRVBRV 200 mg/Day to OLTP BRV
Started000646874
Completed000606768
Not completed000416
Withdrew: Adverse event000200
Withdrew: Lack of efficacy000002
Withdrew: Withdrawal by subject000111
Withdrew: Withdrawal by parent/guardian000001
Withdrew: Patient not keen to continue open label000100
Withdrew: Patient non compliant to open label study drug000001
Withdrew: Subject enrolled to compassionate use program000001

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Treatment-Emergent AEs were defined as AEs which had onset on or after the first dose of IMP. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.

Time frame:
From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsPlaceboBRV 50 mg/DayBRV 200 mg/DayPlacebo to OLTP BRVBRV 50 mg/Day to OLTP BRVBRV 200 mg/Day to OLTP BRV
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)58.457.060.126.619.123.0
PrimaryPercentage of Participants With Treatment-Emergent AEs (TEAEs) Leading to Study Withdrawal

An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. Treatment-Emergent AEs were defined as AEs which had onset on or after the first dose of IMP. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.

Time frame:
From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent AEs (TEAEs) Leading to Study Withdrawal
percentage of participantsPlaceboBRV 50 mg/DayBRV 200 mg/DayPlacebo to OLTP BRVBRV 50 mg/Day to OLTP BRVBRV 200 mg/Day to OLTP BRV
Percentage of Participants With Treatment-Emergent AEs (TEAEs) Leading to Study Withdrawal4.72.63.4000
PrimaryPercentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)

Serious Adverse event (SAE) was defined as any events which: • results in death, • is life-threatening threatening (note that this did not include a reaction that might have caused death had it occurred in a more severe form.), •results in significant or persistent disability/incapacity, • results in a congenital anomaly/birth defect (including that occurring in a fetus), • results in Important medical event that, based upon appropriate medical judgment, may jeopardize the participant and might require medical or surgical intervention to prevent 1 of the other outcomes listed here, and • results in initial inpatient hospitalization or prolongation of hospitalization. As per planned analysis, safety data for all study periods was combined excluding Open-Label Temporary period.

Time frame:
From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (up to 4 Years 10 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)
percentage of participantsPlaceboBRV 50 mg/DayBRV 200 mg/DayPlacebo to OLTP BRVBRV 50 mg/Day to OLTP BRVBRV 200 mg/Day to OLTP BRV
Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)0.71.32.74.702.7
PrimaryPartial Seizure Frequency Per 28 Days During the 12-week Treatment Period

According to International League Against Epilepsy (ILAE) classification (1981), seizures were classified as type IA (IA1, IA2, IA3, and IA4), IB, IC, II (IIA, IIB, IIC, IID, IIE, and IIF) or III. 28 day adjusted seizure frequency for partial seizures (seizure types IA+IB+IC) was calculated for treatment period by dividing the number of partial seizures by the number of days for which the DRC was completed for treatment period and multiplying the resulting value by 28.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Median · seizures per 28 days
Partial Seizure Frequency Per 28 Days During the 12-week Treatment Period
seizures per 28 daysPlaceboBRV 50 mg/DayBRV 200 mg/Day
Partial Seizure Frequency Per 28 Days During the 12-week Treatment Period7.17 (1.0 to 317.0)5.93 (0.0 to 123.7)4.19 (0.0 to 269.4)
Statistical analysis
  • Placebo vs BRV 50 mg/Day · ANCOVA · p = 0.0005 (Statistical testing with control of Type I error rate were based on a Hochberg multiple comparison procedure.) · Percent reduction over placebo: 24.5 · 95% CI 11.7 to 35.5Based on ANCOVA with log-transformed \[log(x+1)\] Treatment Period 28-day adjusted partial seizure frequency.
  • Placebo vs BRV 200 mg/Day · ANCOVA · p = <0.0001 (Statistical testing with control of Type I error rate were based on a Hochberg multiple comparison procedure.) · Percent reduction over placebo: 33.4 · 95% CI 21.9 to 43.1Based on ANCOVA with log-transformed \[log(x+1)\] Treatment Period 28-day adjusted partial seizure frequency.
Secondary50% Responder Rate Based on Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period

Responders were those participants with at least 50% reduction from Baseline to the 12-week Treatment Period in partial seizure frequency per 28 days. 50% Responder rate was calculated for treatment period by dividing the number of 50% responders by the number of participants in the analysis set and multiplying the resulting value by 100.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Number · percentage of responders
50% Responder Rate Based on Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period
percentage of respondersPlaceboBRV 50 mg/DayBRV 200 mg/Day
50% Responder Rate Based on Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period19.0 (13.0 to 26.3)41.1 (33.1 to 49.3)49.3 (41.0 to 57.7)
SecondaryPercent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period

Percent change from Baseline to the Treatment Period in partial seizure frequency was calculated by subtracting 28-day adjusted Treatment Period partial seizure frequency from 28-day adjusted Baseline Period partial seizure frequency, and multiplying the resulting quantity by 100 and dividing by the Baseline Period 28-day adjusted partial seizure frequency. A negative value in percent change from Baseline indicates a decrease in partial seizure frequency from Baseline to the Treatment Period.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Median · percent change
Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period
percent changePlaceboBRV 50 mg/DayBRV 200 mg/Day
Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period21.3 (-123 to 87)38.9 (-233 to 100)46.7 (-1097 to 100)
SecondaryPercentage of Participants With Categorized Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period

The percentage of participants within each of the following categories of percent change in partial seizure frequency from Baseline to the Treatment Period were summarized for each treatment group: 100%, 75% to less than 100%, 50% to less than 75%, 25% to less than 50%, -25% to less than 25%, and less than -25%. Percent change from Baseline to the Treatment Period in partial seizure frequency was calculated by subtracting 28-day adjusted Treatment Period partial seizure frequency from 28-day adjusted Baseline Period partial seizure frequency and multiplying the resulting quantity by 100 and dividing by the Baseline Period 28-day adjusted partial seizure frequency.

Time frame:
From Baseline to 12-week Treatment Period
Reported as:
Number · percentage of participants
Percentage of Participants With Categorized Percent Change in Partial Seizure Frequency Per 28 Days From Baseline to the 12-week Treatment Period
percentage of participantsPlaceboBRV 50 mg/DayBRV 200 mg/Day
100%05.37.4
75% to less than 100%3.414.617.6
50% to less than 75%15.621.224.3
25% to less than 50%27.216.620.9
-25% to less than 25%42.931.118.2
less than-25%10.911.311.5
SecondaryAll Seizure Frequency (Partial, Generalized, and Unclassified Epileptic Seizures) Per 28 Days During the 12-week Treatment Period

There were three types of epileptic seizures: Partial epileptic seizures (Type I), Generalized epileptic seizures (Type II) and unclassified epileptic seizures (Type III). 28 day adjusted seizure frequency for all seizure types was calculated for treatment period by dividing the number of targeted seizures by the number of days for which the DRC was completed for treatment period and multiplying the resulting value by 28.

Time frame:
During the 12-week Treatment Period
Reported as:
Median · seizures per 28 days
All Seizure Frequency (Partial, Generalized, and Unclassified Epileptic Seizures) Per 28 Days During the 12-week Treatment Period
seizures per 28 daysPlaceboBRV 50 mg/DayBRV 200 mg/Day
All Seizure Frequency (Partial, Generalized, and Unclassified Epileptic Seizures) Per 28 Days During the 12-week Treatment Period7.17 (1.0 to 317.0)5.93 (0.0 to 123.7)4.19 (0.0 to 269.4)
SecondaryPercentage of Participants Who Are Seizure Free (Partial, All Epileptic Seizures) During the 12-week Treatment Period

Participants were defined as seizure free, if they did not have missing diary days and no reported seizures during the Treatment Period.

Time frame:
During the 12-week Treatment Period
Reported as:
Number · percentage of participants
Percentage of Participants Who Are Seizure Free (Partial, All Epileptic Seizures) During the 12-week Treatment Period
percentage of participantsPlaceboBRV 50 mg/DayBRV 200 mg/Day
All epileptic seizures04.66.8
Partial onset seizures04.66.8
SecondaryTime to 1st Partial Seizure During the 12-week Treatment Period

The evaluation of time to 1st partial seizure was based on the relative day of occurrence of the 1st partial seizure during the Treatment Period.

Time frame:
During the 12-week Treatment Period
Reported as:
Median · days
Time to 1st Partial Seizure During the 12-week Treatment Period
daysPlaceboBRV 50 mg/DayBRV 200 mg/Day
Time to 1st Partial Seizure During the 12-week Treatment Period3 (2 to 3)5 (3 to 6)6 (5 to 8)
SecondaryTime to 5th Partial Seizure During the 12-week Treatment Period

The evaluation of time to 5th partial seizure was based on the relative day of occurrence of the 5th partial seizure during the Treatment Period.

Time frame:
During the 12-week Treatment Period
Reported as:
Median · days
Time to 5th Partial Seizure During the 12-week Treatment Period
daysPlaceboBRV 50 mg/DayBRV 200 mg/Day
Time to 5th Partial Seizure During the 12-week Treatment Period17 (15 to 21)28 (23 to 36)32 (29 to 38)
SecondaryTime to 10th Partial Seizure During the 12-week Treatment Period

The evaluation of time to 10th partial seizure was based on the relative day of occurrence of the 10th partial seizure during the Treatment Period.

Time frame:
During the 12-week Treatment Period
Reported as:
Median · days
Time to 10th Partial Seizure During the 12-week Treatment Period
daysPlaceboBRV 50 mg/DayBRV 200 mg/Day
Time to 10th Partial Seizure During the 12-week Treatment Period43 (32 to 52)59 (48 to 76)69 (59 to NA)
SecondaryBrivaracetam Plasma Concentration

Blood samples were collected at indicated time points for the 50mg/day and 200mg/day groups to determine the brivaracetam plasma concentration. Participants of arm 'BRV 200 mg/day' received BRV 200 mg/day until Week 12 only and 150 mg/day during the Transition Period at Week 14. Therefore, the data is reported according to the dosage information at specified time point. As per planned analysis, one blood sample was collected for BRV plasma levels during each dosing interval between 0 to 4 hours, 4 to 8 hours, and 8 to 12 hours postdose.

Time frame:
Plasma samples were collected at >0-4hours, >4-8hours, >8hours in weeks 2, 4, 8, 12, and 14
Reported as:
Geometric mean · microgram/ millilitre (ug/mL)
Brivaracetam Plasma Concentration
microgram/ millilitre (ug/mL)BRV 50 mg/DayBRV 200 mg/DayBRV 150 mg/Day
Week 2: > 0 - 4 hours0.68556 ± 95.63.4340 ± 42.5—
Week 2: > 4 - 8 hours0.66523 ± 38.62.0615 ± 334.4—
Week 2: > 8 hours0.18427 ± 979.41.2144 ± 100.1—
Week 4: > 0 - 4 hours0.75902 ± 88.83.0038 ± 120.2—
Week 4: > 4 - 8 hours0.64781 ± 39.22.8516 ± 43.2—
Week 4: > 8 hours0.39652 ± 54.71.1054 ± 74.4—
Week 8: > 0 - 4 hours0.76942 ± 87.32.9983 ± 127.7—
Week 8: > 4 - 8 hours0.76172 ± 34.02.7030 ± 54.9—
Week 8: > 8 hours0.27840 ± 10.91.5590 ± 67.7—
Week 12: > 0 - 4 hours0.77400 ± 89.53.2508 ± 121.1—
Week 12: > 4 - 8 hours0.65274 ± 39.41.6017 ± 838.9—
Week 12: > 8 hours0.18229 ± 579.51.5001 ± 45.4—
Week 14 (Transition): > 0 - 4 hours0.75949 ± 85.3—2.4989 ± 54.8
Week 14 (Transition): > 4 - 8 hours0.75692 ± 34.6—1.4383 ± 309.5
Week 14 (Transition): > 8 hours0.41286 ± 66.4—0.82681 ± 30.6

Adverse events

Collected over From start of the Treatment Period (Week 0) until Safety Visit (up to Week 18); only for OLTP- From last visit of Transition Period to beginning of MAP (Up to 4 Years 10 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/149 (0%)1/149 (0.7%)39/149 (26.2%)
BRV 50 mg/Day1/151 (0.7%)2/151 (1.3%)42/151 (27.8%)
BRV 200 mg/Day0/148 (0%)4/148 (2.7%)54/148 (36.5%)
Placebo to OLTP BRV0/64 (0%)3/64 (4.7%)3/64 (4.7%)
BRV 50 mg/Day to OLTP BRV0/68 (0%)0/68 (0%)4/68 (5.9%)
BRV 200 mg/Day to OLTP BRV0/74 (0%)2/74 (2.7%)4/74 (5.4%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPlaceboBRV 50 mg/DayBRV 200 mg/DayPlacebo to OLTP BRVBRV 50 mg/Day to OLTP BRVBRV 200 mg/Day to OLTP BRV
SeizureNervous system disorders0/1490/1510/1482/640/680/74
Near drowningInjury, poisoning and procedural complications0/1490/1510/1481/640/680/74
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/1490/1510/1481/640/680/74
Respiratory failureRespiratory, thoracic and mediastinal disorders0/1490/1510/1481/640/680/74
ConcussionInjury, poisoning and procedural complications0/1490/1510/1481/640/681/74
HyponatraemiaMetabolism and nutrition disorders0/1490/1510/1480/640/681/74
Cervicogenic headacheNervous system disorders0/1490/1510/1480/640/681/74
DizzinessNervous system disorders0/1490/1510/1480/640/681/74
Large intestine polypGastrointestinal disorders0/1490/1511/1480/640/680/74
PyrexiaGeneral disorders0/1490/1511/1480/640/680/74
Most frequent other events
Most frequent other events
EventPlaceboBRV 50 mg/DayBRV 200 mg/DayPlacebo to OLTP BRVBRV 50 mg/Day to OLTP BRVBRV 200 mg/Day to OLTP BRV
SomnolenceNervous system disorders12/14915/15128/1480/640/680/74
DizzinessNervous system disorders6/14917/15121/1480/640/680/74
HeadacheNervous system disorders11/14911/1517/1480/640/680/74
NasopharyngitisInfections and infestations10/1497/15110/1483/644/684/74
Upper respiratory tract infectionInfections and infestations7/14910/1518/1480/640/680/74

Baseline characteristics

Baseline Characteristics refer to the Randomized Set (RS) which consisted of all study participants who were randomized to investigational medicinal product (IMP).

Age, Categorical
Age, Categorical(Participants)PlaceboBRV 50 mg/DayBRV 200 mg/DayTotal
<=18 years914831
Between 18 and 65 years137135138410
>=65 years3328
Age, Continuous
Age, Continuous(years)PlaceboBRV 50 mg/DayBRV 200 mg/DayTotal
Mean34.5 ± 13.233.7 ± 12.635.2 ± 13.234.5 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBRV 50 mg/DayBRV 200 mg/DayTotal
Female827783242
Male677565207
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBRV 50 mg/DayBRV 200 mg/DayTotal
Asian149152148449
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBRV 50 mg/DayBRV 200 mg/DayTotal
Hispanic or Latino1113
Not Hispanic or Latino148151147446
08

Study locations

94 sites
  • Ep0083 905
    Beijing, China
  • Ep0083 906
    Beijing, China
  • Ep0083 907
    Changchun, China
  • Ep0083 901
    Chengdu, China
  • Ep0083 902
    Guangzhou, China
  • Ep0083 909
    Guangzhou, China
  • Ep0083 917
    Guangzhou, China
  • Ep0083 920
    Guangzhou, China
  • Ep0083 922
    Guangzhou, China
  • Ep0083 924
    Guangzhou, China
  • Ep0083 912
    Hangzhou, China
  • Ep0083 908
    Lanzhou, China
  • Ep0083 921
    Nanchang, China
  • Ep0083 926
    Pingxiang, China
  • Ep0083 910
    Shijiazhuang, China
  • Ep0083 925
    Suzhou, China
  • Ep0083 913
    Wenzhou, China
  • Ep0083 927
    Xi'an, China
  • Ep0083 930
    Xinxiang, China
  • Ep0083 916
    Yinchuan, China
  • Ep0083 918
    Zhanjiang, China
  • Ep0083 904
    Zhengzhou, China
  • Ep0083 923
    Zunyi, China
  • Ep0083 148
    Adachi-ku, Japan
  • Ep0083 116
    Asaka, Japan
  • Ep0083 126
    Bunkyō City, Japan
  • Ep0083 127
    Bunkyō City, Japan
  • Ep0083 146
    Chiba, Japan
  • Ep0083 122
    Hachinohe, Japan
  • Ep0083 111
    Hamamatsu, Japan
  • Ep0083 141
    Higashisonogi-gun Kawatana-cho, Japan
  • Ep0083 110
    Hiroshima, Japan
  • Ep0083 121
    Itami, Japan
  • Ep0083 102
    Kagoshima, Japan
  • Ep0083 142
    Kamakura, Japan
  • Ep0083 140
    Kawasaki, Japan
  • Ep0083 123
    Kodaira, Japan
  • Ep0083 115
    Kokubunji, Japan
  • Ep0083 132
    Kōriyama, Japan
  • Ep0083 112
    Kōshi, Japan
  • Ep0083 128
    Kurume, Japan
  • Ep0083 124
    Kyoto, Japan
  • Ep0083 147
    Kyoto, Japan
  • Ep0083 105
    Nagakute, Japan
  • Ep0083 118
    Nagoya, Japan
  • Ep0083 136
    Nagoya, Japan
  • Ep0083 117
    Nara, Japan
  • Ep0083 129
    Neyagawa, Japan
  • Ep0083 106
    Niigata, Japan
  • Ep0083 130
    Ôsaka, Japan
  • Ep0083 131
    Ōtsu, Japan
  • Ep0083 114
    Saitama, Japan
  • Ep0083 101
    Sapporo, Japan
  • Ep0083 103
    Sendai, Japan
  • Ep0083 144
    Shinjuku-ku, Japan
  • Ep0083 104
    Shizuoka, Japan
  • Ep0083 108
    Suita, Japan
  • Ep0083 137
    Suita, Japan
  • Ep0083 138
    Tsukuba, Japan
  • Ep0083 133
    Ushiku, Japan
  • Ep0083 109
    Yamagata, Japan
  • Ep0083 120
    Yokohama, Japan
  • Ep0083 150
    Yokohama, Japan
  • Ep0083 207
    Kota Bharu, Malaysia
  • Ep0083 201
    Kuala Lumpur, Malaysia
  • Ep0083 206
    Kuala Terengganu, Malaysia
  • Ep0083 204
    Kuching, Malaysia
  • Ep0083 209
    Miri, Malaysia
  • Ep0083 202
    Perai, Malaysia
  • Ep0083 208
    Pulau Pinang, Malaysia
  • Ep0083 203
    Sungai Buloh, Malaysia
  • Ep0083 303
    Cebu City, Philippines
  • Ep0083 304
    Cebu City, Philippines
  • Ep0083 306
    Davao City, Philippines
  • Ep0083 307
    Iloilo City, Philippines
  • Ep0083 301
    Manila, Philippines
  • Ep0083 302
    Manila, Philippines
  • Ep0083 310
    Manila, Philippines
  • Ep0083 309
    Quezon City, Philippines
  • Ep0083 401
    Singapore, Singapore
  • Ep0083 402
    Singapore, Singapore
  • Ep0083 502
    Chiayi City, Taiwan
  • Ep0083 505
    Kaohsiung City, Taiwan
  • Ep0083 503
    Taichung, Taiwan
  • Ep0083 504
    Taichung, Taiwan
  • Ep0083 501
    Tainan, Taiwan
  • Ep0083 602
    Bangkok, Thailand
  • Ep0083 605
    Bangkok, Thailand
  • Ep0083 606
    Bangkok, Thailand
  • Ep0083 607
    Bangkok, Thailand
  • Ep0083 609
    Bangkok, Thailand
  • Ep0083 601
    Khon Kaen, Thailand
  • Ep0083 603
    Muang, Thailand
  • Ep0083 608
    Muang, Thailand
09

References and documents

Publications

  • Usui N, Zhou D, Qin B, Tiamkao S, Cabral-Lim L, Lim KS, Lim SH, Tsai JJ, Watanabe J, Sun W, Dickson N, Moseley B, Bourikas D, Inoue Y. Temporal Profile of Treatment-Emergent Adverse Events in Adult Asian Patients with Focal-Onset Seizures During Adjunctive Brivaracetam Treatment: Post Hoc Analysis of a Phase 3, Randomized Trial. Adv Ther. 2025 Nov;42(11):5639-5652. doi: 10.1007/s12325-025-03357-7. Epub 2025 Sep 13. PubMed 40944847 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jun 2022, 58 months.

Results were first posted in Nov 2023, 1 year 4 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 58 months is above that.

Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2017
First posted
Mar 20, 2017
StartActual
Aug 22, 2017
Primary completionActual
Jun 30, 2022
CompletionActual
Jun 30, 2022
Results first posted
Nov 9, 2023
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03083665
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Mar 20, 2017
Start date
Aug 22, 2017
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Results posted
Nov 9, 2023
Last update
Oct 14, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion